Enliven Therapeutics, Inc. (ELVN) Stock
5 of the hedge funds AlphaScala tracks reported ELVN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $105.00M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which hedge funds own ELVN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 2.07M | $105.00M | +19% |
| Marshall Wace | 532K | $27.01M | NEW |
| Millennium Management Israel Englander | 411K | $20.88M | +19% |
| D.E. Shaw David Shaw | 306K | $15.51M | +58% |
| Blackstone | 216K | $10.95M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Enliven Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 19, 26 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 5.0K | $192K |
| Oct 19, 26 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | SELL | 6.0K | $232K |
| Oct 1, 26 | Garland J. Scott | Director | SELL | 13.0K | $607K |
| Sep 17, 26 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 2.9K | $146K |
| Sep 17, 26 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 1.8K | $94K |
| Sep 17, 26 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 240 | $12K |
| Sep 17, 26 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | SELL | 3.5K | $177K |
| Sep 17, 26 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | SELL | 2.2K | $111K |
| Sep 17, 26 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | SELL | 289 | $15K |
| Aug 17, 26 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 3.9K | $228K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →ELVN price chart
Powered by TradingViewWhat does Enliven Therapeutics, Inc. do?
Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases. The primary focus of the company lies in advancing the field of precision medicine, which aims to tailor medical treatment to the individual characteristics of each patient, enhancing treatment efficacy and minimizing side effects. Enliven Therapeutics Inc. is actively engaged in researching and developing targeted therapies that address unmet medical needs across various therapeutic areas, particularly concentrating on genetic disorders and oncology. By leveraging cutting-edge technology platforms and innovative research methodologies, Enliven Therapeutics seeks to offer groundbreaking treatments that have a significant impact on patient care and outcomes. The company plays a vital role in the pharmaceutical and healthcare sectors, contributing to the rapid evolution of personalized healthcare solutions. In the financial market, Enliven Therapeutics represents an integral component of the biotechnology sector, often garnering interest from investors focused on emerging biotech innovations and their potential to transform traditional medical practices.